Bi-heteroaryl substitute 1,4-benzodiazepines and uses thereof for the treatment of cancer

US11542247B2 · kind B2 · utility

Assignee

• Janssen Pharmaceuticals, Inc. · BE

Inventors

• Patrick René Angibaud · Louviers, FR
• Diego Broggini · Schaffhausen, CH
• Filip Albert C Cuyckens · Aartselaar, BE
• Steven Anna Hostyn · Hove, BE
• Russell Mark Jones · Binningen, CH
• Olivier Alexis Georges Querolle · Évreux, FR
• Wim Vermeulen · Vosselaar, BE

Key dates

• Filing date: Sep 22, 2016
• Grant date: Jan 3, 2023
• Expiry date: Jun 4, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D471/04
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The invention relates to new quinoline, pyridopyrazine, naphthyridine and quinazolinone derivative compounds, to pharmaceutical compositions comprising said compounds, to processes for the preparation of said compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.